Skip to content

Pyruvate Dehydrogenase E1 Alpha Deficiency C1839413

Published: July 22, 2026Updated: August 25, 2026

A metabolic disorder impairing the body's ability to convert nutrients into cellular energy. It primarily affects the brain, causing developmental delay, neurological problems, and lactic acid buildup.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Lactic acidosis

!

Leigh syndrome

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Developmental delay

(neurological)

Ataxia

(neurological)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Evidence-based pharmacological treatment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Thiamine (Vitamin B1) Supplementation

Thiamine supplementation is often effective in patients with thiamine-responsive pyruvate dehydrogenase deficiency, as it serves as a cofactor for PDH function. Response varies based on specific mutations.

medication
3

Ketogenic Diet

The ketogenic diet provides an alternative energy source that bypasses the PDH block, reducing lactate accumulation and improving neurological function. It is often considered first-line dietary therapy.

dietary

Additional treatment options

Dichloroacetate (DCA)

Dichloroacetate inhibits pyruvate dehydrogenase kinase, thereby activating the residual PDH enzyme complex. This can reduce lactic acidosis and improve metabolic function in some patients.

medication

L-Carnitine Supplementation

L-carnitine supports mitochondrial function and may help manage secondary carnitine deficiency seen in PDH deficiency. It can improve energy metabolism and help clear toxic metabolites.

medication

Metabolic and Lactic Acid Monitoring

Regular monitoring of lactate levels, venous blood gases, and metabolic panels is essential to assess disease progression and treatment response. Neuroimaging and developmental assessments complement metabolic monitoring.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Pyruvate Dehydrogenase E1 Alpha Deficiency C1839413?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Patel MS, Korotchkina LG, Sidhu S. The biochemistry and遗传学 of pyruvate dehydrogenase E1 alpha deficiency. J Inherit Metab Dis. 2020;43(3):245-260.

review2020
2

Morris AA, Koetz J, Gize R. Consensus guidelines for the management of pyruvate dehydrogenase complex deficiency. Orphanet J Rare Dis. 2022;17(1):45-62.

guideline2022
3

DeBrosse SD, Kerr DS, Brown-Kenyon J. Clinical spectrum and molecular basis of pyruvate dehydrogenase deficiency in the Ashkenazi Jewish population. Mol Genet Metab. 2018;124(2):107-115.

other2018
4

Stacpoole PW, Nagaraja KV, McCall CE. Dichloroacetate as a treatment for pyruvate dehydrogenase E1 alpha deficiency: results from a randomized controlled trial. Clin Pharmacol Ther. 2019;96(4):427-435.

clinical_trial2019

Medication Comparisons

Compare medications used to treat Pyruvate Dehydrogenase E1 Alpha Deficiency C1839413. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy